Fully Automated Hematology Analyzers Market will reach at $ 23.32 billion by 2032Segments Analysis by Top Key Players :Sysmex Corporation, Beckman Coulter, Inc, Abbott Laboratories, Siemens Healthcare, Horiba, Ltd., Bio-Rad Laboratories, Inc., Boule Diagn

Market Overview
Fully Automated Hematology Analyzers Market will reach at $ 23.32 billion by 2032
The hematology analyzers market is projected to register a CAGR of 7.6% during the forecast period.

There is an increasing focus on the hematology parameters for the assessment of COVID-19 around the world. Several studies are carried out in research institutions, and many of the hospitals started using the hematology analyzers to test and monitor COVID-19 patients without spreading the virus. For the practical and efficient screening of the large populations for the COVID-19 infection, some research studies from China recommended including white blood cells (WBC) and C-reactive protein (CRP) in laboratory examinations for early monitoring of infection. On March 18, 2020, Sight announced that Israel's government-run Sheba Tel Hashomer Hospital is using its OLO, the first blood count device for point-of-care to conduct CBC tests to monitor and treat its COVID-19 patients to mitigate the risk of contamination.

Scope of the Report
As per the scope of this report, hematology analyzers are the equipment used to run tests on blood samples, and they are used in the medical field to determine white blood cell counts, complete blood counts, reticulocyte analysis, and coagulation tests. The hematology analyzers market is segmented by product (instruments (3 part hematology analyzer, 5 part hematology analyzer, point-of-care testing hematology analyzers, and others), reagents, and services), end users (hospitals, clinical laboratories, and research institutes, and other end users), and geography (North America, Europe, Asia Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Leading players of Fully Automated Hematology Analyzers including:

Sysmex Corporation, Beckman Coulter, Inc, Abbott Laboratories, Siemens Healthcare, Horiba, Ltd., Bio-Rad Laboratories, Inc., Boule Diagnostics Ab, Mindray Medical International Limited, Nihon Kohden Corporation, Roche Diagnostics

Free Sample Report + All Related Graphs & Charts @ https://www.mraccuracyreports.com/report-sample/350073

Key Market Trends
3 Part Hematology Analyzer is the Segment by Instruments Expected to Hold Largest Market Share
With the rising COVID-19 cases, and the lockdown and inhibitions on the intercountry transport were found having an impact on the supply chain of the systems. Initially many manufacturers have thus stopped the production due to the lack of labor that is found impacting the segment growth. However, the increasing focus on hematology parameters for the assessment of COVID-19 has increased the demand for hematology analyzers. In the case of the COVID-19 pandemic, 3- part hematology analyzers found to be cost-effective as the samples required to test is huge. Furthermore, demand may surge post the COVID-19 pandemic also.

Moreover, A 3-part differential cell counter uses Coulter's Principle to find the size and volume of the cell. The sample is lysed and dissolved into an electrolyte solution in a container, which also holds a smaller container. 3-part hematology analyzer systems are ideally suited for physician office laboratories, clinics, and small hospitals that perform moderately complex testing. There is increased interest on 5-part hematology analyzers, however, 3-part hematology analyzers are more cost-effective for routine hematological tests. Furthermore, with advancements in technology and availability of these instruments across the world coupled with affordability the market is projected to have notable growth.

In March 2019, Transasia Bio-Medicals Ltd has launched the 3-Part Differential (3PD) fully automated hematology analyzers, reagents and controls in India that were manufactured by Erba Lachema a fully owned European subsidiary of Transasia. Later in September 2019, Transasia Bio-Medicals Ltd. has announced that it has successfully sold over 1,000 units of its Erba Hematology range of analyzers in India.

In April 2019, Prestige Diagnostics has launched its NEW Hematron 3 PLUS Hematology Analyzer, globally. It is a 3-part differential hematology analyzer capable of performing 18 parameters with 3 histograms.

Furthermore, the clinical laboratories as end users are the centers where hematology tests are performed. Usually, they have high-quality equipment and the results obtained from them are accurate. The automation of laboratories have increased the equipment costs in this segment, however, the analyzers are not frequently replaced in these laboratories. The clinical testing laboratories perform various tests on whole blood, serum, urine, cerebrospinal fluids, and other body fluids. Furthermore, convenience and accurate results are the two major reasons driving the growth of the segment over the forecast period.

North America is Expected to Dominate the Studied Market
The rising COVID-19 cases and the lockdown and inhibitions on the intercountry transport were found to have an impact on the supply chain of the systems. Initially, many manufacturers have thus stopped production due to the lack of labor that is found impacting the segment growth. However, the increasing focus on hematology parameters for the assessment of COVID-19 has increased the demand for hematology analyzers. In the case of the COVID-19 pandemic, 3-part hematology analyzers were found to be cost-effective as the samples required to test are huge. Furthermore, demand may surge post the COVID-19 pandemic also.

Moreover, A 3-part differential cell counter uses Coulter's Principle to find the size and volume of the cell. The sample is lysed and dissolved into an electrolyte solution in a container, which holds a smaller container. 3-part hematology analyzer systems are ideally suited for physician office laboratories, clinics, and small hospitals that perform moderately complex testing. There is increased interest in 5-part hematology analyzers. However, 3-part hematology analyzers are more cost-effective for routine hematological tests. Furthermore, with advancements in technology and availability of these instruments across the world coupled with affordability, the market is projected to have notable growth.

In March 2019, Transasia Bio-Medicals Ltd launched the 3-Part Differential (3PD) fully automated hematology analyzers, reagents, and controls in India manufactured by Erba Lachema, a fully owned European subsidiary of Transasia. Later in September 2019, Transasia Bio-Medicals Ltd. announced that it has successfully sold over 1,000 units of its Erba Hematology range of analyzers in India.

In April 2019, Prestige Diagnostics launched its NEW Hematron 3 PLUS Hematology Analyzer, globally. It is a 3-part differential hematology analyzer capable of performing 18 parameters with 3 histograms.

Furthermore, the clinical laboratories as end users are the centers where hematology tests are performed. Usually, they have high-quality equipment, and the results obtained from them are accurate. The automation of laboratories has increased the equipment costs in this segment. However, analyzers are not frequently replaced in these laboratories. The clinical testing laboratories perform various tests on whole blood, serum, urine, cerebrospinal fluids, and other body fluids. Furthermore, convenience and accurate results are the two major reasons driving the growth of the segment over the forecast period.

The United States is one of the most COVID-affected countries across the world. Due to the outbreak of COVID-19, the market is expected to face a slight setback owing to the delay in diagnosis, drug shortages, and others. However The outbreak of COVID-19 is expected to impact the market, as individuals with blood conditions, such as hemophilia, should take extra precautions to minimize the risk of contracting COVID-19, as this group of the population is more prone to infectious diseases.

The market for hematology analyzers in the North American region is growing at a steady pace. This can be attributed to the increasing burden of blood disorders and the growth in the adoption of hematology analyzers by the diagnostic industry. For instance, anemia, which is a common disorder, affects more than three million Americans, particularly women of 'childbearing age.

According to the World Federation of Hemophilia 2018 report, in 2018, there were about 17,757 people diagnosed with hemophilia in the United States. Furthermore, in 2019, the number of people with hemophilia in the United States increased to about 20,000 individuals, as per NHF (National Health Federation). According to the Leukemia and Lymphoma Society, every three minutes, a person in the United States is diagnosed with blood cancer. About 176,200 people in the United States were diagnosed with leukemia, lymphoma, or myeloma, in 2019.

Fully Automated Hematology Analyzers Segmentation by Type:

Type I, Type II.

Fully Automated Hematology Analyzers Segmentation by Application:

Application I, Application II

Fully Automated Hematology Analyzers report answers some key questions:

Recent Developments
In May 2020, the University Hospital of Montpellier (CHU de Montpellier) collaborated with HORIBA Medical to use Microsemi CRP and Pentra MS CRP hematology analyzers for sorting the patients for the project for the development of biomarkers predictive of a poorer respiratory evolution associated with positive screening for the COVID-19 infection.
In February 2021, the company Beckman Coulter announced the launch of DxH 560 AL, a tabletop hematology analyzer.
The report provides Fully Automated Hematology Analyzers industry demand trends in Q1 and Q2 2021.
• Individual circumstances of the Fully Automated Hematology Analyzers segments are discussed in the report.
• The report contains forward-looking information on risks and uncertainties.
• The report studies the consumer-focused sectors of the Fully Automated Hematology Analyzers.
• The trade scenarios of the products and services in particular segments are detailed in the report along with regulation, taxes, and tariffs.
• The trends that are impacting the Fully Automated Hematology Analyzers for past few years are discussed in the report.
• The report studies the potential impact of the Covid-19 pandemic on the Fully Automated Hematology Analyzers industry economy and performance of the market players in the same context.
Please click here today to buy full report @ https://www.mraccuracyreports.com/checkout/350073

Table of Content:

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered
2 Executive Summary
3 Global Fully Automated Hematology Analyzers by Players
4 Fully Automated Hematology Analyzers by Regions
4.1 Fully Automated Hematology Analyzers Size by Regions
4.2 Americas Fully Automated Hematology Analyzers Size Growth
4.3 APAC Fully Automated Hematology Analyzers Size Growth
4.4 Europe Fully Automated Hematology Analyzers Size Growth
4.5 Middle East & Africa Fully Automated Hematology Analyzers Size Growth
5 Americas
6 APAC
7 Europe
8 Middle East & Africa
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Global Fully Automated Hematology Analyzers Forecast
11 Key Players Analysis
12 Research Findings and Conclusion

MR Accuracy Reports is the number one publisher in the world and have published more than 2 million reports across globe. Fortune 500 companies are working with us. Also helping small players to know the market and focusing on consulting.

Call Us - UK +44 7452119323
USA +1 8045001224
Email us - sales@mraccuracyreports.com
30 Crawley Lane, West Sussex, RH10 7EG, United Kingdom
3351 Green Turtle Rd, Regina, SK S4V 3N6, Canada

MR Accuracy Reports is a Market Research and consulting company that accomplishes requirement of research agencies,small, medium and large corporations, global business leaders, government organizations,
SME's, Individual & Start-ups, top management consulting firms

This release was published on openPR.